Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.
An emerging paradigm for the treatment of primary immunodeficiency disease (PIDD) with immunoglobulin (IgG) replacement therapy emphasizes the tailoring of treatments to each patient with the goal of preventing infections and minimizing side effects. Increasing evidence shows that the IgG dose needed to prevent infection varies with each patient, and both intravenous immunoglobulin (IGIV) and subcutaneous immunoglobulin (IGSC) have emerged as feasible modes of delivery. Although IGIV is currently the routine treatment, IGSC is increasingly being chosen as the preferred route of delivery due to greater flexibility and reduced side effects.
Midwest Immunology Clinic, 157300 37th Avenue, Suite 100, Plymouth, MN, 55446, USA. rshapiro@midwestimmunology.com.
Ralph S
RS
Shapiro
Medical City Children's Hospital, Dallas, TX, USA.
Richard L
RL
Wasserman
Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, NY, USA.
Vincent
V
Bonagura
University of California, Irvine, Irvine, CA, USA.
Sudhir
S
Gupta
D000066491:Clinical Decision-Making; D019468:Disease Management; D006801:Humans; D007074:Immunoglobulin G / Q000302:isolation & purification; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D017053:Infection Control; D007239:Infections / Q000209:etiology; D055104:Infusions, Subcutaneous; D057285:Precision Medicine; D016896:Treatment Outcome
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous
IVIG; IgG trough level; Primary immunodeficiency; common variable immunodeficiency; immunoglobulin replacement therapy; subcutaneous immunoglobulin